Associated Papers
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F et al.
Cancer Discovery, 2024
38564707 (PubMed )
Supplement: cd-23-1217_supplementary_table_2_suppst2.pdf
Conserved regulatory motifs in the juxtamembrane domain and kinase N-lobe revealed through deep mutational scanning of the MET receptor tyrosine kinase domain.
Estevam GO et al.
Biorxiv : the Preprint Server for Biology, 2024
Quantitative thresholds for variant enrichment in 13,845 cases: improving pathogenicity classification in genetic hearing loss.
Liu S et al.
Genome Medicine, 2023
38111038 (PubMed )
Supplement: 13073_2023_1271_MOESM1_ESM.xlsx › Table_S6
Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients.
Yang J et al.
Frontiers in Oncology, 2021
33898318 (PubMed )
Supplement: Table_1.xlsx › Sheet1
Spectrum of Mesenchymal-Epithelial Transition Aberrations and Potential Clinical Implications: Insights From Integrative Pancancer Analysis.
Li J et al.
Frontiers in Oncology, 2020
33178590 (PubMed )
Supplement: Table_2.XLSX › ___1
Select a paper to view details